These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 22350135)

  • 81. Sphingosine Kinases/Sphingosine 1-Phosphate Signaling in Hepatic Lipid Metabolism.
    Kwong EK; Li X; Hylemon PB; Zhou H
    Curr Pharmacol Rep; 2017 Aug; 3():176-183. PubMed ID: 29130028
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Training Does Not Alter Muscle Ceramide and Diacylglycerol in Offsprings of Type 2 Diabetic Patients Despite Improved Insulin Sensitivity.
    Søgaard D; Østergård T; Blachnio-Zabielska AU; Baranowski M; Vigelsø AH; Andersen JL; Dela F; Helge JW
    J Diabetes Res; 2016; 2016():2372741. PubMed ID: 27777958
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Ceramides and glucosylceramides are independent antagonists of insulin signaling.
    Chavez JA; Siddique MM; Wang ST; Ching J; Shayman JA; Summers SA
    J Biol Chem; 2014 Jan; 289(2):723-34. PubMed ID: 24214972
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Overexpression of the adiponectin receptor AdipoR1 in rat skeletal muscle amplifies local insulin sensitivity.
    Patel SA; Hoehn KL; Lawrence RT; Sawbridge L; Talbot NA; Tomsig JL; Turner N; Cooney GJ; Whitehead JP; Kraegen EW; Cleasby ME
    Endocrinology; 2012 Nov; 153(11):5231-46. PubMed ID: 22989629
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Human muscle fiber type-specific insulin signaling: impact of obesity and type 2 diabetes.
    Albers PH; Pedersen AJ; Birk JB; Kristensen DE; Vind BF; Baba O; Nøhr J; Højlund K; Wojtaszewski JF
    Diabetes; 2015 Feb; 64(2):485-97. PubMed ID: 25187364
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Skeletal muscle lipid content and oxidative enzyme activity in relation to muscle fiber type in type 2 diabetes and obesity.
    He J; Watkins S; Kelley DE
    Diabetes; 2001 Apr; 50(4):817-23. PubMed ID: 11289047
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Accumulation of ceramide in slow-twitch muscle contributes to the development of insulin resistance in the obese JCR:LA-cp rat.
    Fillmore N; Keung W; Kelly SE; Proctor SD; Lopaschuk GD; Ussher JR
    Exp Physiol; 2015 Jun; 100(6):730-41. PubMed ID: 25786668
    [TBL] [Abstract][Full Text] [Related]  

  • 88. GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease?
    Gaster M; Staehr P; Beck-Nielsen H; Schrøder HD; Handberg A
    Diabetes; 2001 Jun; 50(6):1324-9. PubMed ID: 11375332
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Short-term manipulation of plasma free fatty acids does not change skeletal muscle concentrations of ceramide and glucosylceramide in lean and overweight subjects.
    Serlie MJ; Meijer AJ; Groener JE; Duran M; Endert E; Fliers E; Aerts JM; Sauerwein HP
    J Clin Endocrinol Metab; 2007 Apr; 92(4):1524-9. PubMed ID: 17264178
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Ceramide content is higher in type I compared to type II fibers in obesity and type 2 diabetes mellitus.
    Kristensen D; Prats C; Larsen S; Ara I; Dela F; Helge JW
    Acta Diabetol; 2013 Oct; 50(5):705-12. PubMed ID: 22350135
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Metabolic control of myofibers: promising therapeutic target for obesity and type 2 diabetes.
    Duan Y; Li F; Tan B; Yao K; Yin Y
    Obes Rev; 2017 Jun; 18(6):647-659. PubMed ID: 28391659
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Role of Ceramide in Apoptosis and Development of Insulin Resistance.
    Kuzmenko DI; Klimentyeva TK
    Biochemistry (Mosc); 2016 Sep; 81(9):913-27. PubMed ID: 27682164
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Targeting ceramide metabolism in obesity.
    Aburasayn H; Al Batran R; Ussher JR
    Am J Physiol Endocrinol Metab; 2016 Aug; 311(2):E423-35. PubMed ID: 27382035
    [TBL] [Abstract][Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.